Experimental hyperlipidaemia does not prevent preconditioning and it reduces ischemia-induced apoptosis

Area of Science:

• Cardiovascular Physiology
• Metabolic Research
• Cellular Biology

Background:

• Ischemic preconditioning (PC) offers cardioprotection in healthy individuals.
• The effect of PC in hyperlipidemia, a condition characterized by high blood lipid levels, remains unclear.
• Investigating PC's efficacy in hyperlipidemic states is crucial for understanding its clinical applicability.

Purpose of the Study:

• To determine if hyperlipidemia affects the cardioprotective benefits of ischemic preconditioning (PC).
• To assess the impact of hyperlipidemia on myocardial contractility and apoptosis following ischemia-reperfusion injury.
• To investigate the role of plasma HDL concentrations in hyperlipidemia-associated cardioprotection.

Main Methods:

• Guinea pigs were fed either a normal or a hyperlipidaemic diet for five weeks.
• Papillary muscles were subjected to experimental ischemia-reperfusion.
• The influence of prior PC on contractility and apoptosis was evaluated in both normo- and hyperlipidaemic groups.

Main Results:

• Hyperlipidemia altered lipid parameters but did not impair papillary muscle function under basal or ischemia-reperfusion conditions.
• Hyperlipidemia influenced ischemia-induced apoptosis, with higher HDL levels correlating with reduced susceptibility to injury.
• PC demonstrated cardioprotective effects, reducing apoptosis and preserving contractility in hyperlipidemic guinea pigs.

Conclusions:

• Hyperlipidemia does not negate the cardioprotective benefits of ischemic preconditioning, including reduced apoptosis and preserved myocardial contractility.
• Plasma HDL concentrations may play a protective role against ischemia-induced apoptosis in cardiomyocytes.
• These findings suggest PC remains a viable strategy for cardioprotection even in the presence of hyperlipidemia.